Zenlabs EthicaBOM:530697 -4.96%53 Net Margin % is 0.01% as of Mar. 2026, which is 99% below its 10-year median of 0.93. GuruFocus rates BOM:530697 with a GF Score™ of 53/100 and a GF Value™ of ₹29.37 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 117 Medical Distribution companies, Zenlabs Ethica ranks worse than 81.2% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Zenlabs Ethica's Net Income for the
three
months ended in Mar. 2026 was ₹0.0 Mil. Zenlabs Ethica's Revenue for the
three
months ended in Mar. 2026 was ₹105.8 Mil. Therefore, Zenlabs Ethica's net margin for the quarter that ended in Mar. 2026 was 0.01%.
The historical rank and industry rank for Zenlabs Ethica's Net Margin % or its related term are showing as below:
BOM:530697'
s Net Margin % Range Over the Past 10 Years
Min: -4.13 Med: 0.93 Max: 1.88
Current: -4.13
BOM:530697's Net Margin % is ranked worse than 81.2% of 117
companies
in the Medical Distribution industry
Industry Median: 1.5
vs BOM:530697: -4.13
Zenlabs Ethica (BOM:530697) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Zenlabs Ethica Net Margin % Related Terms
Zenlabs Ethica Net Margin % Historical Data
* Premium members only.
The historical data trend for Zenlabs Ethica's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530697 vs MCK, CAH, COR: Net Margin % Comparison
For the Medical Distribution subindustry, Zenlabs Ethica's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenlabs Ethica Net Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Zenlabs Ethica's Net Margin % distribution charts can be found below:
* The bar in red indicates where Zenlabs Ethica's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenlabs Ethica (BOM:530697) has a Net Margin % of 0.01% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Zenlabs Ethica and its competitors. This is 99% below median its historical median of 0.93. According to the industry distribution chart, Zenlabs Ethica ranks #95 out of 117 companies in the Medical Distribution industry, placing it in the top 81.2%.
Is Zenlabs Ethica's Net Margin % too high?
Zenlabs Ethica's current Net Margin % of 0.01% is 99% below median its 10-year median of 0.93. The Medical Distribution industry median Net Margin % is 1.50. Zenlabs Ethica's value of 0.01% is 99.3% below this industry median. Based on the distribution chart, Zenlabs Ethica ranks #95 out of 117 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Zenlabs Ethica has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zenlabs Ethica's Net Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Zenlabs Ethica ranks #95 out of 117 companies for Net Margin %. This places Zenlabs Ethica in the lower half of its industry. The industry median Net Margin % is 1.50. Zenlabs Ethica's value of 0.01% is 99.3% below this benchmark. While the company's 10-year median is 0.93 vs. the industry median of 1.50, Zenlabs Ethica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Distribution company?
The median Net Margin % among Medical Distribution companies is 1.50, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenlabs Ethica's current Net Margin % of 0.01% is 99.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Zenlabs Ethica and its competitors. For the Medical Distribution industry, the median Net Margin % is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenlabs Ethica's current Net Margin % is 0.01%, which is 99% below median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenlabs Ethica stock overvalued right now?
Based on GuruFocus' analysis, Zenlabs Ethica (BOM:530697) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹29.37, compared to a current price of ₹32.60 — trading 11% above its estimated fair value. The current Net Margin % is 0.01%, which is 99% below median its 10-year median of 0.93 and 99.3% below the Medical Distribution industry median of 1.50. Zenlabs Ethica's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Zenlabs Ethica (BOM:530697), the current Net Margin % is 0.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenlabs Ethica (BOM:530697) Overvalued in 2026?
Based on GuruFocus' analysis, Zenlabs Ethica stock appears to be overvalued.
The current stock price of ₹32.60 is trading 11% above its estimated GF Value™ of ₹29.37.
GuruFocus considers Zenlabs Ethica to be Modestly Overvalued.
Key valuation signals for BOM:530697:
Net Margin %: 0.01% (99% below median its 10-year median of 0.93)
GF Value™: ₹29.37 vs. price of ₹32.60 (11% above fair value)
Industry Position: 99.3% below the Medical Distribution median (#95 of 117)
No single metric tells the full story. See the BOM:530697 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zenlabs Ethica Ltd is a pharmaceutical company engaged in the trading of pharmaceutical formulations. It manufactures and markets drugs which include Gastrointestinal disorders, anti-diabetics, anti-hypertensive drugs, anti-infective, soaps, and anti-Bacterial drugs, nutraceuticals, and others. In addition, The company offers more than 600 products across therapeutic segments.
53GF Score
Get the complete analysis for BOM:530697
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530697 has been successfully added to your 
